Four startups from the Øresund region have secured €2.5 million grants each from the European Innovation Council’s EIC Accelerator programme, after the EIC this week selected 35 deep tech companies out of 453 full applications for its latest funding round, proposing €84 million in grants, with 32 of the companies also to be assessed for equity investments of up to €10 million each by the EIC Fund.

Lund-based AlixLabs, founded in 2019, develops technology to make the production of semiconductors more accessible, sustainable, and affordable. The company has also been selected for the EIC Fund’s equity component, making it eligible for up to €10 million in equity funding in its next financing round. The grant comes after a strong year for the company, which closed a €15 million Series A round in the spring.

“The anticipated €2.5 million grant provides important non-dilutive funding to accelerate our development and industrialization activities, while the potential investment from the EIC Fund represents a strong foundation for our next financing round. Just as importantly, this is an acknowledgment of the role our technology can play in strengthening Europe’s semiconductor ecosystem.”

says Jonas Sundqvist, CEO of AlixLabs.

Lund-based Asgard Therapeutics, founded in 2018, explores direct cell reprogramming technologies to develop ground-breaking cancer immunotherapies. For the company, the EIC Accelerator grant marks the third time it has secured funding from the European Innovation Council, underlining its standing as one of the region’s most consistently EIC-backed life science startups.

“This €2.5 million EIC Accelerator grant caps a fantastic year for Asgard, in which we have made huge progress on the road to becoming a clinical-stage company. Being selected is not only strong recognition of our pioneering direct cell reprogramming approach and the potential of our lead asset AT-108. It will also help us prepare AT-108 quicker, so we are ready for the clinic and start dosing patients next year. In addition, the grant opens the door to a potential equity investment from the EIC Fund of up to €10 million, as part of a wider financing round.”

said Cristiana Pires, Co-founder and CEO of Asgard Therapeutics

Copenhagen-founded Neumirna Therapeutics pioneers RNA-based treatments for neurological diseases, targeting microRNAs, powerful regulators of gene expression, to address the disease rather than treating symptoms alone. The company, founded in 2020 by experts in neuroscience and RNA biology and operating from Copenhagen, Basel, and Boston, has a clinical stage candidate, NMT.001, for drug-resistant epilepsy, as well as a preclinical programme in Parkinson’s disease. Backers include Sunstone Life Science Ventures, Angelini Ventures, and Invivo Partners, which co-led its €20 million Series A.

Copenhagen-based Nordic Salt Cycle, launched in December 2024 and led by CEO Stefan Vilner and CTO James Amphlett, traces its roots back to compact molten salt nuclear reactors, where the team built and operated world-class molten salt facilities. The company has since turned the technology towards recovering Europe’s critical minerals, developing a molten salt process to separate and extract materials such as lithium, cobalt, and rare earth elements from end-of-life products like EV batteries, wind turbines, and electronics, using very little energy and significantly fewer chemicals. The EIC grant will finance the transition from laboratory to industrial scale, including the commissioning of a demonstration plant capable of processing up to 200 tonnes of material per year. The company raised a €3.5 million pre-seed round from EIFO, The Footprint Firm, and Ananda Impact Ventures a year ago.